Arthur H. Jeske, DMD, PhD
LectureThis course is part of the Association for Continuing Dental Education Joint Live Webinar Series.
This course qualifies for providing credit for the DEA MATE Act training requirement.
This course is part of the Association for Continuing Dental Education Joint Live Webinar Series*
Course Description
The ever-increasing death rate associated with the opioid epidemic has brought emergency opioid overdose reversal into the spotlight. With the increased potency and duration of new illicitly-manufactured fentanyl analogs, new strategies for effective opioid reversal are emerging, including the introduction of new opioid antagonists. Additionally, there are parallel concerns for adverse reactions to opioid overdose reversal, including the opioid withdrawal syndrome. This course summarizes current scientific evidence and opinion on the issues surrounding emergency opioid reversal.
Course Objectives
As a result of attending this class, you will be able to:
- Review the pharmacologic characteristics of opioid antagonists
- Describe the signs and symptoms of opioid overdose
- Review the currently recommended methods for administration and dosages of antagonists used to reverse opioid overdose
- Describe the potential adverse effects of opioid reversal and their management
Instructor
Arthur H. Jeske is the Associate Dean for Strategic Planning and Continuing Dental Education and a professor in the Department of General Practice and Dental Public Health at UTHealth School of Dentistry. He earned his PhD in pharmacology and DMD degrees from the Medical College of Georgia. He is a member of the American Dental Association, Texas Dental Association, and Greater Houston Dental Society and is a Fellow of the International College of Dentists and the American College of Dentists. Dr. Jeske chaired the ADA’s Council on Scientific Affairs in 2004 and has authored numerous articles on the use of drugs in dentistry. He is currently Editor-in-Chief of Mosby’s Dental Drug Reference and Editor of Contemporary Dental Pharmacology.
Disclosures:
- Dr. Jeske has no relevant financial relationships to disclose.
- The staff of the University of Washington Office of Continuing Dental Education have no relevant financial relationships to disclose.
Course Logistics
DATE:
Thursday, June 29, 2023
LOCATION:
Online Webinar
TARGET AUDIENCE:
The dental professional
TIMES:
5:00pm – 6:30pm Pacific Standard time
TUITION:
$59/Participant
CREDITS:
1.5 hours
*The University of Washington in conjunction with the Association for Continuing Dental Education (ACDE), along with 30 of its member schools jointly presents the “ACDE Webinar Series”
This series features university-based key opinion leaders presenting numerous topics on multiple dates and times. Presentations are available to meet every dental health care professional’s schedule and interests.
The University of Washington is an ADA CERP Recognized Provider.
ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.
This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint efforts between the University of Washington and Oregon Health Sciences University.
The University of Washington is a member of the Association for Continuing Dental Education.
University of Washington designates this activity for 1.5 continuing education credits.